ImmunityBio, Inc.
IBRX
Classement en actions
#2135
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Prix de l'action
$9.08
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$9.62B
Changement (1 jour)
-9.25%
Changement (1 an)
278.13%
Pays
US
Échange ImmunityBio, Inc. (IBRX)
Catégorie
Healthcare
Marge opérationnelle de ImmunityBio, Inc. (IBRX)
Marge opérationnelle au October 2026 TTM : -151.88%
Selon les derniers rapports financiers et le cours de l'action de ImmunityBio, Inc., la marge opérationnelle actuelle (TTM) est de -151.88%. À la fin de 2023, elle était de -58,239.55%.
Historique de la marge opérationnelle pour ImmunityBio, Inc. de 2013 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | -151.88% | -93.49% |
| 2024 | -2,334.23% | -95.99% |
| 2023 | -58,239.55% | -60.21% |
| 2022 | -146,374.17% | 313.93% |
| 2021 | -35,361.88% | -3.14% |
| 2020 | -36,509.09% | 414.51% |
| 2019 | -7,095.87% | -96.61% |
| 2018 | -209,338.30% | -4.96% |
| 2017 | -220,266.67% | -22.15% |
| 2016 | -282,954.55% | 179.55% |
| 2015 | -101,218.64% | 10,344.49% |
| 2014 | -969.11% | 156.26% |
| 2013 | -378.17% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 38.59% | -100.25% |
US
|
|
| -149.01% | -99.02% |
US
|
|
| 25.57% | -100.17% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.19% |
NL
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.